Innovative drug delivery technologies will play an increasingly important role in the future development of cancer therapy. The application of advances in drug delivery technologies to cancer therapy will be governed by directions in the development of anticancer drugs. Important areas of development are cancer pharmacogenomics and cancer gene therapy. Decision Resources, Inc., announces a new report that evaluates numerous drug delivery strategies that are being developed in tandem with emerging therapeutics, Drug Delivery in Cancer: Technologies and Commercial Opportunities.

  (Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )    Key features of this report include the following:   --Illustrates the relevance of genomics and pharmacogenomics to cancer     drug delivery.   --Evaluates unmet needs in cancer drug delivery and the potential of     emerging technologies-including gene therapy, antisense technology, and     monoclonal antibodies-to meet these needs.   --Analyzes strategic and commercial aspects of developing and marketing     cancer drug delivery technologies.   --Estimates the market value of selected innovative technologies in cancer     drug delivery for 2000, 2005, and 2010 in the seven major pharmaceutical     markets (United States, France, Germany, Italy, Spain, United Kingdom,     and Japan.   --Profiles 17 companies developing innovative drug delivery technologies.  

Gene therapy appears to be one of the best methods of therapeutic delivery in cancer. A few products that are in Phase III trials, such as Vical's Allovectin-7 for metastatic melanoma, will be on the market before 2005, when the cancer gene therapy market is expected to be worth $2 billion. This market, which is expected to expand to $3 billion by 2010, will be the most important segment of novel drug delivery for cancer. If one combines antisense therapy and nucleic acid vaccines (genetic vaccination), gene-based medicines will clearly dominate the cancer drug delivery market of 2010.

Drug Delivery in Cancer: Technologies and Commercial Opportunities is available for $3,200.00. Contact: Cindy Ohlman, 781.296.2521 (telephone), 781.296.2525 (fax), or ohlman@dresources.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail). http://www.dresources.com

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends.

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Cindy Ohlman of Decision Resources, Inc., 781-296-2521,
ohlman@dresources.com

Decision Resources Study Evaluates Promising Antivirals and Vaccines in Development to Treat Influenza

View Now